Serveur d'exploration MERS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors

Identifieur interne : 000297 ( Ncbi/Checkpoint ); précédent : 000296; suivant : 000298

Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors

Auteurs : Richard J. Fish ; Egbert Ko Kruithof

Source :

RBID : PMC:514603

Descripteurs français

English descriptors

Abstract

Background

RNA interference (RNAi) can potently reduce target gene expression in mammalian cells and is in wide use for loss-of-function studies. Several recent reports have demonstrated that short double-stranded RNAs (dsRNAs), used to mediate RNAi, can also induce an interferon-based response resulting in changes in the expression of many interferon-responsive genes. Off-target gene silencing has also been described, bringing into question the validity of certain RNAi-based approaches for studying gene function. We have targeted the plasminogen activator inhibitor-2 (PAI-2 or SERPINB2) mRNA using lentiviral vectors for delivery of U6 promoter-driven PAI-2-targeted short hairpin RNA (shRNA) expression. PAI-2 is reported to have anti-apoptotic activity, thus reduction of endogenous expression may be expected to make cells more sensitive to programmed cell death.

Results

As expected, we encountered a cytotoxic phenotype when targeting the PAI-2 mRNA with vector-derived shRNA. However, this predicted phenotype was a potent non-specific effect of shRNA expression, as functional overexpression of the target protein failed to rescue the phenotype. By decreasing the shRNA length or modifying its sequence we maintained PAI-2 silencing and reduced, but did not eliminate, cytotoxicity. ShRNA of 21 complementary nucleotides (21 mers) or more increased expression of the oligoadenylate synthase-1 (OAS1) interferon-responsive gene. 19 mer shRNA had no effect on OAS1 expression but long-term selective pressure on cell growth was observed. By lowering lentiviral vector titre we were able to reduce both expression of shRNA and induction of OAS1, without a major impact on the efficacy of gene silencing.

Conclusions

Our data demonstrate a rapid cytotoxic effect of shRNAs expressed in human tumor cell lines. There appears to be a cut-off of 21 complementary nucleotides below which there is no interferon response while target gene silencing is maintained. Cytotoxicity or OAS1 induction could be reduced by changing shRNA sequence or vector titre, but stable gene silencing could not be maintained in extended cell culture despite persistent marker gene expression from the RNAi-inducing transgene cassette. These results underscore the necessity of careful controls for immediate and long-term RNAi use in mammalian cell systems.


Url:
DOI: 10.1186/1471-2199-5-9
PubMed: 15291968
PubMed Central: 514603


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

PMC:514603

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors</title>
<author>
<name sortKey="Fish, Richard J" sort="Fish, Richard J" uniqKey="Fish R" first="Richard J" last="Fish">Richard J. Fish</name>
<affiliation>
<nlm:aff id="I1">Division of Angiology and Haemostasis, Department of Internal Medicine, Geneva University Hospital and University Medical Centre, Geneva, CH-1211 Switzerland</nlm:aff>
<wicri:noCountry code="subfield">CH-1211 Switzerland</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Kruithof, Egbert Ko" sort="Kruithof, Egbert Ko" uniqKey="Kruithof E" first="Egbert Ko" last="Kruithof">Egbert Ko Kruithof</name>
<affiliation>
<nlm:aff id="I1">Division of Angiology and Haemostasis, Department of Internal Medicine, Geneva University Hospital and University Medical Centre, Geneva, CH-1211 Switzerland</nlm:aff>
<wicri:noCountry code="subfield">CH-1211 Switzerland</wicri:noCountry>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">15291968</idno>
<idno type="pmc">514603</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC514603</idno>
<idno type="RBID">PMC:514603</idno>
<idno type="doi">10.1186/1471-2199-5-9</idno>
<date when="2004">2004</date>
<idno type="wicri:Area/Pmc/Corpus">000553</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000553</idno>
<idno type="wicri:Area/Pmc/Curation">000553</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000553</idno>
<idno type="wicri:Area/Pmc/Checkpoint">001428</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">001428</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15291968</idno>
<idno type="wicri:Area/PubMed/Corpus">002374</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002374</idno>
<idno type="wicri:Area/PubMed/Curation">002374</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002374</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002235</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002235</idno>
<idno type="wicri:Area/Ncbi/Merge">000297</idno>
<idno type="wicri:Area/Ncbi/Curation">000297</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000297</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors</title>
<author>
<name sortKey="Fish, Richard J" sort="Fish, Richard J" uniqKey="Fish R" first="Richard J" last="Fish">Richard J. Fish</name>
<affiliation>
<nlm:aff id="I1">Division of Angiology and Haemostasis, Department of Internal Medicine, Geneva University Hospital and University Medical Centre, Geneva, CH-1211 Switzerland</nlm:aff>
<wicri:noCountry code="subfield">CH-1211 Switzerland</wicri:noCountry>
</affiliation>
</author>
<author>
<name sortKey="Kruithof, Egbert Ko" sort="Kruithof, Egbert Ko" uniqKey="Kruithof E" first="Egbert Ko" last="Kruithof">Egbert Ko Kruithof</name>
<affiliation>
<nlm:aff id="I1">Division of Angiology and Haemostasis, Department of Internal Medicine, Geneva University Hospital and University Medical Centre, Geneva, CH-1211 Switzerland</nlm:aff>
<wicri:noCountry code="subfield">CH-1211 Switzerland</wicri:noCountry>
</affiliation>
</author>
</analytic>
<series>
<title level="j">BMC Molecular Biology</title>
<idno type="eISSN">1471-2199</idno>
<imprint>
<date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>2',5'-Oligoadenylate Synthetase (genetics)</term>
<term>Biomarkers (metabolism)</term>
<term>Cell Line</term>
<term>Cell Line, Tumor</term>
<term>Drug Delivery Systems (methods)</term>
<term>Enzyme Induction (genetics)</term>
<term>Gene Expression (genetics)</term>
<term>Gene Silencing</term>
<term>Gene Transfer Techniques</term>
<term>Genetic Vectors (genetics)</term>
<term>HeLa Cells (drug effects)</term>
<term>Humans</term>
<term>Kidney (cytology)</term>
<term>Kidney (drug effects)</term>
<term>Kidney (embryology)</term>
<term>Lentivirus (genetics)</term>
<term>Lentivirus (metabolism)</term>
<term>Plasminogen Activator Inhibitor 2 (biosynthesis)</term>
<term>Plasminogen Activator Inhibitor 2 (genetics)</term>
<term>Plasminogen Activator Inhibitor 2 (metabolism)</term>
<term>RNA Stability</term>
<term>RNA, Antisense (administration & dosage)</term>
<term>RNA, Antisense (adverse effects)</term>
<term>RNA, Antisense (metabolism)</term>
<term>RNA, Messenger (genetics)</term>
<term>RNA, Messenger (metabolism)</term>
<term>RNA, Small Interfering (adverse effects)</term>
<term>RNA, Small Interfering (biosynthesis)</term>
<term>RNA, Small Interfering (metabolism)</term>
<term>Transduction, Genetic (methods)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>2',5'-Oligoadenylate synthetase (génétique)</term>
<term>ARN antisens (administration et posologie)</term>
<term>ARN antisens (effets indésirables)</term>
<term>ARN antisens (métabolisme)</term>
<term>ARN messager (génétique)</term>
<term>ARN messager (métabolisme)</term>
<term>Cellules HeLa ()</term>
<term>Expression des gènes (génétique)</term>
<term>Extinction de l'expression des gènes</term>
<term>Humains</term>
<term>Induction enzymatique (génétique)</term>
<term>Inhibiteur-2 d'activateur du plasminogène (biosynthèse)</term>
<term>Inhibiteur-2 d'activateur du plasminogène (génétique)</term>
<term>Inhibiteur-2 d'activateur du plasminogène (métabolisme)</term>
<term>Lentivirus (génétique)</term>
<term>Lentivirus (métabolisme)</term>
<term>Lignée cellulaire</term>
<term>Lignée cellulaire tumorale</term>
<term>Marqueurs biologiques (métabolisme)</term>
<term>Petit ARN interférent (biosynthèse)</term>
<term>Petit ARN interférent (effets indésirables)</term>
<term>Petit ARN interférent (métabolisme)</term>
<term>Rein ()</term>
<term>Rein (cytologie)</term>
<term>Rein (embryologie)</term>
<term>Stabilité de l'ARN</term>
<term>Systèmes de délivrance de médicaments ()</term>
<term>Techniques de transfert de gènes</term>
<term>Transduction génétique ()</term>
<term>Vecteurs génétiques (génétique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>RNA, Antisense</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>RNA, Antisense</term>
<term>RNA, Small Interfering</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en">
<term>Plasminogen Activator Inhibitor 2</term>
<term>RNA, Small Interfering</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en">
<term>2',5'-Oligoadenylate Synthetase</term>
<term>Plasminogen Activator Inhibitor 2</term>
<term>RNA, Messenger</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Biomarkers</term>
<term>Plasminogen Activator Inhibitor 2</term>
<term>RNA, Antisense</term>
<term>RNA, Messenger</term>
<term>RNA, Small Interfering</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>ARN antisens</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr">
<term>Inhibiteur-2 d'activateur du plasminogène</term>
<term>Petit ARN interférent</term>
</keywords>
<keywords scheme="MESH" qualifier="cytologie" xml:lang="fr">
<term>Rein</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en">
<term>Kidney</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>HeLa Cells</term>
<term>Kidney</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr">
<term>ARN antisens</term>
<term>Petit ARN interférent</term>
</keywords>
<keywords scheme="MESH" qualifier="embryologie" xml:lang="fr">
<term>Rein</term>
</keywords>
<keywords scheme="MESH" qualifier="embryology" xml:lang="en">
<term>Kidney</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en">
<term>Enzyme Induction</term>
<term>Gene Expression</term>
<term>Genetic Vectors</term>
<term>Lentivirus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr">
<term>2',5'-Oligoadenylate synthetase</term>
<term>ARN messager</term>
<term>Expression des gènes</term>
<term>Induction enzymatique</term>
<term>Inhibiteur-2 d'activateur du plasminogène</term>
<term>Lentivirus</term>
<term>Vecteurs génétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Lentivirus</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Drug Delivery Systems</term>
<term>Transduction, Genetic</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>ARN antisens</term>
<term>ARN messager</term>
<term>Inhibiteur-2 d'activateur du plasminogène</term>
<term>Lentivirus</term>
<term>Marqueurs biologiques</term>
<term>Petit ARN interférent</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Cell Line</term>
<term>Cell Line, Tumor</term>
<term>Gene Silencing</term>
<term>Gene Transfer Techniques</term>
<term>Humans</term>
<term>RNA Stability</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Cellules HeLa</term>
<term>Extinction de l'expression des gènes</term>
<term>Humains</term>
<term>Lignée cellulaire</term>
<term>Lignée cellulaire tumorale</term>
<term>Rein</term>
<term>Stabilité de l'ARN</term>
<term>Systèmes de délivrance de médicaments</term>
<term>Techniques de transfert de gènes</term>
<term>Transduction génétique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<sec>
<title>Background</title>
<p>RNA interference (RNAi) can potently reduce target gene expression in mammalian cells and is in wide use for loss-of-function studies. Several recent reports have demonstrated that short double-stranded RNAs (dsRNAs), used to mediate RNAi, can also induce an interferon-based response resulting in changes in the expression of many interferon-responsive genes. Off-target gene silencing has also been described, bringing into question the validity of certain RNAi-based approaches for studying gene function. We have targeted the plasminogen activator inhibitor-2 (PAI-2 or SERPINB2) mRNA using lentiviral vectors for delivery of U6 promoter-driven PAI-2-targeted short hairpin RNA (shRNA) expression. PAI-2 is reported to have anti-apoptotic activity, thus reduction of endogenous expression may be expected to make cells more sensitive to programmed cell death.</p>
</sec>
<sec>
<title>Results</title>
<p>As expected, we encountered a cytotoxic phenotype when targeting the PAI-2 mRNA with vector-derived shRNA. However, this predicted phenotype was a potent non-specific effect of shRNA expression, as functional overexpression of the target protein failed to rescue the phenotype. By decreasing the shRNA length or modifying its sequence we maintained PAI-2 silencing and reduced, but did not eliminate, cytotoxicity. ShRNA of 21 complementary nucleotides (21 mers) or more increased expression of the oligoadenylate synthase-1 (OAS1) interferon-responsive gene. 19 mer shRNA had no effect on OAS1 expression but long-term selective pressure on cell growth was observed. By lowering lentiviral vector titre we were able to reduce both expression of shRNA and induction of OAS1, without a major impact on the efficacy of gene silencing.</p>
</sec>
<sec>
<title>Conclusions</title>
<p>Our data demonstrate a rapid cytotoxic effect of shRNAs expressed in human tumor cell lines. There appears to be a cut-off of 21 complementary nucleotides below which there is no interferon response while target gene silencing is maintained. Cytotoxicity or OAS1 induction could be reduced by changing shRNA sequence or vector titre, but stable gene silencing could not be maintained in extended cell culture despite persistent marker gene expression from the RNAi-inducing transgene cassette. These results underscore the necessity of careful controls for immediate and long-term RNAi use in mammalian cell systems.</p>
</sec>
</div>
</front>
<back>
<div1 type="bibliography">
<listBibl>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations>
<list></list>
<tree>
<noCountry>
<name sortKey="Fish, Richard J" sort="Fish, Richard J" uniqKey="Fish R" first="Richard J" last="Fish">Richard J. Fish</name>
<name sortKey="Kruithof, Egbert Ko" sort="Kruithof, Egbert Ko" uniqKey="Kruithof E" first="Egbert Ko" last="Kruithof">Egbert Ko Kruithof</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000297 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000297 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    RBID
   |clé=     PMC:514603
   |texte=   Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i   -Sk "pubmed:15291968" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a MersV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021